NASDAQ:XBIT XBiotech (XBIT) Stock Price, News & Analysis $2.97 +0.17 (+6.07%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About XBiotech Stock (NASDAQ:XBIT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get XBiotech alerts:Sign Up Key Stats Today's Range$2.85▼$3.0550-Day Range$2.50▼$3.1652-Week Range$2.50▼$8.32Volume131,607 shsAverage Volume70,604 shsMarket Capitalization$90.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewXBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.Read More… XBiotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreXBIT MarketRank™: XBiotech scored higher than 13% of companies evaluated by MarketBeat, and ranked 898th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for XBiotech. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of XBiotech is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XBiotech is -2.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXBiotech has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about XBiotech's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.11% of the float of XBiotech has been sold short.Short Interest Ratio / Days to CoverXBiotech has a short interest ratio ("days to cover") of 17.9, which indicates bearish sentiment.Change versus previous monthShort interest in XBiotech has recently increased by 28.43%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXBiotech does not currently pay a dividend.Dividend GrowthXBiotech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.11% of the float of XBiotech has been sold short.Short Interest Ratio / Days to CoverXBiotech has a short interest ratio ("days to cover") of 17.9, which indicates bearish sentiment.Change versus previous monthShort interest in XBiotech has recently increased by 28.43%, indicating that investor sentiment is decreasing significantly. News and Social Media3.5 / 5News Sentiment1.28 News SentimentXBiotech has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for XBiotech this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added XBiotech to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XBiotech insiders have not sold or bought any company stock.Percentage Held by Insiders33.10% of the stock of XBiotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.70% of the stock of XBiotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about XBiotech's insider trading history. Receive XBIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter. Email Address XBIT Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBITFebruary 4, 2025 | prnewswire.comXBiotech stock hits 52-week low at $3.5 amid market challengesJanuary 28, 2025 | msn.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.June 30 at 2:00 AM | Brownstone Research (Ad)XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law FirmJanuary 17, 2025 | prnewswire.comWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities lawsJanuary 14, 2025 | globenewswire.comXBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law FirmJanuary 13, 2025 | businesswire.comXBiotech Inc.'s (NASDAQ:XBIT) largest shareholders are individual investors with 49% ownership, insiders own 35%January 10, 2025 | finance.yahoo.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBITJanuary 8, 2025 | prnewswire.comSee More Headlines XBIT Stock Analysis - Frequently Asked Questions How have XBIT shares performed this year? XBiotech's stock was trading at $3.95 at the beginning of the year. Since then, XBIT stock has decreased by 24.8% and is now trading at $2.97. View the best growth stocks for 2025 here. How were XBiotech's earnings last quarter? XBiotech Inc. (NASDAQ:XBIT) posted its quarterly earnings data on Wednesday, May, 14th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter. When did XBiotech IPO? XBiotech (XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO. How do I buy shares of XBiotech? Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XBiotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that XBiotech investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AU Optronics (AUOTY). Company Calendar Last Earnings5/14/2025Today6/30/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XBIT CIK1626878 Webwww.xbiotech.com Phone(512) 386-2900Fax512-386-5505Employees100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.53 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.14% Return on Assets-19.55% Debt Debt-to-Equity RatioN/A Current Ratio29.15 Quick Ratio29.15 Sales & Book Value Annual Sales$4.01 million Price / Sales22.58 Cash FlowN/A Price / Cash FlowN/A Book Value$5.98 per share Price / Book0.50Miscellaneous Outstanding Shares30,490,000Free Float20,396,000Market Cap$90.56 million OptionableOptionable Beta0.98 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:XBIT) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XBiotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.